⚠ Biosimilars Get BetterModerate threat

The protection that biologic complexity affords rests on copies being hard to make — and the industry is steadily getting better at making them. Biosimilar development, once slow, uncertain, and expensive, has matured: more biosimilars reach the market, regulators have streamlined their approval, and specialist manufacturers have built real expertise in copying complex biologics. As that capability improves, the manufacturing moat that gave biologics a gentle patent cliff and a long tail erodes, and the competition after patent expiry grows more effective.

The danger is that Lilly's assumption of a soft landing for its biologic franchises may prove too optimistic over time. If biosimilars become faster to develop, cheaper to make, and more readily substituted, the price erosion after a biologic's patent expires could come to resemble the brutal generic cliff of small molecules more than the gentle decline biologics have historically enjoyed. The extra years of protection manufacturing complexity has bought could shorten as the copiers close the gap.

Lilly's most complex drugs still enjoy genuine manufacturing protection, and biosimilar competition remains meaningfully harder and slower than generic competition for now. But an owner should recognize that the difficulty of copying biologics is a diminishing barrier rather than a permanent one, that the biosimilar industry is advancing, and that the comfortable assumption of long, gentle tails on Lilly's biologic franchises depends on a manufacturing advantage the rest of the industry — Novo's build-out included¹ — is steadily learning to overcome.